



Model List of Essential Medicines

Anti-D immunoglobulin

| Section | Indications |
|---|---------------------------------------|
| Human immunoglobulins Parenteral > General injections > IV: 250 µg in single-dose vial Parenteral > General injections > IM: 250 µg in single-dose vial | Maternal care for red cell antibodies |

Carbetocin

| Section | Indications |
|--|------------------------|
| Uterotonics Parenteral > General injections > IV: 100 µg per mL (heat stable) | Postpartum haemorrhage |

Carboplatin

| Section | Indications |
|--|-------------------------------------|
| Cytotoxic medicines Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL | Other specified carcinomas of ovary |

Cisplatin

| Section | Indications |
|--|-------------------------------------|
| Cytotoxic medicines Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL | Malignant neoplasms of cervix uteri |

Clomifene

| Section | Indications |
|---|---|
| Ovulation inducers Oral > Solid: 50 mg (citrate) | Female infertility without specification whether primary or secondary |

Copper-containing intrauterine device

| Section | Indications |
|---------------------------|--|
| Intrauterine devices - | Contact with health services for insertion of contraceptive device |

Dexamethasone

| Section | Indications |
|---|--|
| Other medicines administered to the mother Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium)) | Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy |

Ergometrine

| Section | Indications |
|--|------------------------|
| Uterotonics Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate) | Postpartum haemorrhage |

Estradiol cypionate + medroxyprogesterone acetate

| Section | Indications |
|--|---|
| Injectable hormonal contraceptives Parenteral > General injections > IM: 5 mg + 25 mg | Contact with health services for reasons associated with reproduction |

Ethinylestradiol + etonogestrel

| Section | Indications |
|---|---|
| Intravaginal contraceptives Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg | Contact with health services for contraceptive management |

Ethinylestradiol + levonorgestrel

| Section | Indications |
|--|---|
| Oral hormonal contraceptives Oral > Solid: 50 µg + 250 µg [4] | Contact with health services for postcoital contraception |
| Oral > Solid: 30 µg + 150 µg | Contact with health services for contraceptive management |

Ethinylestradiol + norethisterone

| Section | Indications |
|--|---|
| Oral hormonal contraceptives Oral > Solid: 35 µg + 1 mg | Contact with health services for contraceptive management |

Etonogestrel-releasing implant

| Section | Indications |
|---|--|
| Implantable contraceptives Implant > Subdermal: 68 mg single rod | Contact with health services for insertion of contraceptive device |

Folic acid

| Section | Indications |
|---|---|
| Antianaemia medicines Oral > Solid: 400 µg | Anencephaly or similar anomalies Spina bifida Cephalocele |

Levonorgestrel

| Section | Indications |
|--|--|
| Oral hormonal contraceptives Oral > Solid: 750 µg [2]; 1.5 mg [1] Oral > Solid: 30 µg | Contact with health services for postcoital contraception Contact with health services for contraceptive management |
| Intrauterine devices Intrauterine system with reservoir containing 52 mg of levonorgestrel. | Contact with health services for insertion of contraceptive device |

Levonorgestrel-releasing implant

| Section | Indications |
|---|--|
| Implantable contraceptives Implant > Subdermal: 75 mg per rod (two-rods) | Contact with health services for insertion of contraceptive device |

Medroxyprogesterone acetate

| Section | Indications |
|---|---|
| Injectable hormonal contraceptives Parenteral > General injections > IM: 150 mg per mL in 1 mL vial Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system | Contact with health services for reasons associated with reproduction |
| Progestogens Oral > Solid: 5 mg | Excessive menstruation with irregular cycle |

Methydopa

| Section | Indications |
|----------------------------|--------------------------|
| Antihypertensive medicines | Gestational hypertension |
| Oral > Solid: 250 mg | |

Methylergometrine

| Section | Indications |
|-------------|---|
| Uterotonics | Therapeutic equivalent to ergometrine for Postpartum haemorrhage |

Mifepristone - misoprostol

| Section | Indications |
|--|--|
| Uterotonics | Induced abortion |
| Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package | Unspecified time of fetal death, cause not specified |

Misoprostol

| Section | Indications |
|---------------------------------|--|
| Uterotonics | Spontaneous abortion, incomplete, without complication |
| Oral > Solid: 200 µg | Unspecified obstetric condition |
| Local > Vaginal > tablet: 25 µg | Postpartum haemorrhage |

Multiple micronutrient supplement

| Section | Indications |
|---|--|
| <p>Other medicines administered to the mother</p> <p>Tablet containing:</p> <p>Vit A: 800 mcg retinol activity equivalent</p> <p>Vit C: 70 mg</p> <p>Vit D: 5 mcg (200 IU)</p> <p>Vit E: 10 mg alpha tocopherol equivalent</p> <p>Vit B1: 1.4 mg</p> <p>Vit B2: 1.4 mg</p> <p>Vit B3: 18 mg niacin equivalent</p> <p>Vit B6: 1.9 mg</p> <p>Folic acid: 400 mcg</p> <p>Vit B12: 2.6 mcg</p> <p>Iron: 30 mg</p> <p>Iodine: 150 mcg</p> <p>Zinc: 15 mg</p> <p>Selenium: 65 mcg</p> <p>Copper: 2 mg</p> | <p>Maternal care for other specified conditions predominantly related to pregnancy</p> |

Nifedipine

| Section | Indications |
|---|--|
| <p>Antioxytocics (tocolytics)</p> <p>Oral > Solid: 10 mg (immediate-release)</p> | <p>Preterm labour without delivery</p> |

Norethisterone

| Section | Indications |
|--|---|
| <p>Oral hormonal contraceptives</p> <p>Oral > Solid: 350 µg</p> | <p>Contact with health services for contraceptive management</p> |
| Progesterogens | <p>Therapeutic equivalent to medroxyprogesterone acetate for</p> <p>Excessive menstruation with irregular cycle</p> |

Norethisterone enantate

| Section | Indications |
|--|--|
| <p>Injectable hormonal contraceptives</p> <p>Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution</p> | <p>Contact with health services for reasons associated with reproduction</p> |

Oxytocin

| Section | Indications |
|--|------------------------|
| Uterotonics Parenteral > General injections > unspecified: 10 IU per mL | Postpartum haemorrhage |

Progesterone vaginal ring

| Section | Indications |
|--|---|
| Intravaginal contraceptives Local > Vaginal > vaginal ring: 2.074 g micronized progesterone | Contact with health services for contraceptive management |

Simvastatin

| Section | Indications |
|--|---------------------------|
| Medicines for endocrine disorders Oral > Solid: 20 mg | Polycystic ovary syndrome |

Sulfadoxine + pyrimethamine

| Section | Indications |
|---|--------------------------------------|
| Antimalarial medicines > For chemoprevention Oral > Solid: 500 mg + 25 mg tablet | Malaria due to Plasmodium falciparum |

Tranexamic acid

| Section | Indications |
|--|------------------------|
| Other medicines administered to the mother Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule | Postpartum haemorrhage |

Ulipristal

| Section | Indications |
|---|---|
| Oral hormonal contraceptives Oral > Solid: 30 mg tablet (ulipristal acetate) | Contact with health services for postcoital contraception |